BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17466053)

  • 1. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix.
    Uno T; Mitsuhashi A; Isobe K; Yamamoto S; Kawakami H; Ueno N; Usui H; Tate S; Kawata T; Ito H
    Int J Gynecol Cancer; 2008; 18(1):80-4. PubMed ID: 17466053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer.
    Sood BM; Timmins PF; Gorla GR; Garg M; Anderson PS; Vikram B; Goldberg GL
    Int J Gynecol Cancer; 2002; 12(5):459-64. PubMed ID: 12366663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
    Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
    Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Yuxing Y; Devi CR; Bustam AZ; Calaguas MJ; de los Reyes RH; Cho CK; Dung TA; Supriana N; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):751-7. PubMed ID: 19836154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
    Kim JS; Kim JS; Kim SY; Kim Ki; Cho MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1247-53. PubMed ID: 12654434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.
    Small W; Winter K; Levenback C; Iyer R; Gaffney D; Asbell S; Erickson B; Jhingran A; Greven K
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1081-7. PubMed ID: 17398031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
    Sood BM; Gorla G; Gupta S; Garg M; Deore S; Runowicz CD; Fields AL; Goldberg GL; Anderson PS; Vikram B
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):702-6. PubMed ID: 12062615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is a low dose of concomitant chemotherapy with extended-field radiotherapy acceptable as an efficient treatment for cervical cancer patients with metastases to the para-aortic lymph nodes?
    Kazumoto T; Kato S; Yokota H; Hasumi Y; Kino N; Horie K; Yoshida D; Mizukami T; Saito Y
    Int J Gynecol Cancer; 2011 Nov; 21(8):1465-71. PubMed ID: 21892097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparative Study of Clinical Outcomes in Locally Advanced Cervical Cancer: External Beam Radiotherapy (EBRT) and Sequential High Dose Rate Intracavitary Brachytherapy (HDRICBT) with or without Concurrent Cisplatin on the Day of ICBT Insertion - A Tertiary Care Center Randomized Controlled Trial in India.
    Alim S; Siddiqui SA; Akram M; Hakim S; Khan MA
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1333-1338. PubMed ID: 38679994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.